Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
This study is currently recruiting participants.
Verified April 2013
by Roswell Park Cancer Institute
Study NCT01250470 Information provided by Roswell Park Cancer Institute
First Received on November 24, 2010. Last Updated on April 30, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Mixed Glioma
Recurrent Adult Brain Tumor
Additional conditions recognized in this trial
Astrocytoma
Brain Neoplasms
Glioblastoma
Glioma
Gliosarcoma
Oligodendroglioma
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Nervous System Neoplasms
Neuroectodermal Tumors
Interventions listed in this trial
sargramostim
flow cytometry
laboratory biomarker analysis
immunoenzyme technique
Additional drug interventions recognized in this trial
Freund's Adjuvant
More general drug interventions related to this trial
Adjuvants, Immunologic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Back to top of Main Content
